Function-preserving CD8⁺ T Cell Immunogenicity minimization through protein design
Rapid advances in protein design enable new approaches in adoptive cell therapy, but foreign proteins can elicit cytotoxic T cell responses, and hence there is considerable need for approaches which reduce immunogenicity without compromising protein function. Here, we develop a computational framework integrating structure-guided sequence design with MHC class I epitope prediction to efficiently tune protein immunogenicity while preserving function. Using a de novo-designed luciferase as a model, we demonstrate epitope elimination while preserving function across 5 common mouse alleles and extend our computational optimization to 25 common human MHC-I alleles. In mice immunized with mRNA-lipid nanoparticles, variants designed to have few MHC-I epitopes elicited little detectable CD8⁺ T cell response, whereas variants designed to include multiple epitopes induced robust responses. Together, these results demonstrate that the CD8⁺ T cell immunogenicity of designed proteins can be tuned while preserving function, opening the door to incorporation of designed proteins in a next generation of adoptive cell therapies.
Authors
- Bingxu Liu (ORCID: https://orcid.org/0000-0002-3661-3410)
- Tianyang Mao (ORCID: https://orcid.org/0000-0001-9251-8592)
- Nir Hacohen (ORCID: https://orcid.org/0000-0002-2349-2656)
- David A. Baker (ORCID: https://orcid.org/0000-0001-7896-6217)
- Oliver Morell (ORCID: https://orcid.org/0009-0000-8702-1792)
- Max H. Witwer (ORCID: https://orcid.org/0009-0007-9520-9163)
Institutions
- Broad Institute (US)
- University of Washington (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-10-27
- DOI
- https://doi.org/10.64898/2026.10.24.761497
- Primary Topic
- vaccines and immunoinformatics approaches
- Type
- preprint
Funders
- U.S. Department of Defense
- Howard Hughes Medical Institute
- Jane Coffin Childs Memorial Fund for Medical Research
- Mark Foundation For Cancer Research
- Cancer Research UK
- National Cancer Institute